Targeting of extracellular proteases required for the progression of pancreatic cancer.

Expert Opinion on Therapeutic Targets
Christine M ArditoHoward C Crawford

Abstract

Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States. Its lethality is due, in large part, to its resistance to traditional chemotherapeutics. As a result, there is an enormous effort being put into basic research to identify proteins that are required for PDA progression so that they may be specifically targeted for therapy. To compile and analyze the evidence that suggests that extracellular proteases are significant contributors to PDA progression. We focus on three different extracellular protease subclasses expressed in PDA: metalloproteases, serine proteases and cathepsins. Based on data from PDA and other cancers, we suggest their probable roles in PDA. Of the proteases expressed in PDA, many appear to have overlapping functions, based on the substrates they process, making therapeutics complicated. Two protease families most likely to have unique, critical functions during tumor progression, and therefore strong potential as therapeutic targets, are the a disintegrin and metalloproteases (ADAMs) and the cathepsins.

References

Nov 1, 1992·Experimental Cell Research·P RagnoJ D Vassalli
Jul 1, 1994·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·H Maruta, A W Burgess
Aug 7, 1996·International Journal of Cancer. Journal International Du Cancer·T AzumaM Nakajima
Jan 1, 1996·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·H FriessM W Büchler
Sep 18, 1997·Journal of the National Cancer Institute·A F Chambers, L M Matrisian
Dec 10, 1997·Journal of the National Cancer Institute·M J Tisdale
Nov 18, 1998·Current Opinion in Cell Biology·R A Black, J M White
Dec 10, 1999·International Journal of Cancer. Journal International Du Cancer·V EllenriederT M Gress
Feb 9, 2000·The Journal of Cell Biology·B M Gumbiner
Mar 16, 2000·The EMBO Journal·U FelborW Mothes
Jun 13, 2000·Advances in Experimental Medicine and Biology·M M LerchB Krüger
Aug 30, 2000·International Journal of Cancer. Journal International Du Cancer·J R ConejoM W Büchler
Sep 9, 2000·Current Opinion in Cell Biology·C P Blobel
Oct 12, 2000·Nature Cell Biology·G BergersD Hanahan
Feb 24, 2001·International Journal of Pancreatology : Official Journal of the International Association of Pancreatology·M NiedergethmannS Post
May 31, 2001·The Journal of Cell Biology·M KajitaM Seiki
Jun 19, 2001·International Journal of Cancer. Journal International Du Cancer·V EllenriederT M Gress
Aug 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S R BramhallUNKNOWN Marimastat Pancreatic Cancer Study Group
Sep 18, 2001·International Journal of Pancreatology : Official Journal of the International Association of Pancreatology·Y ItoN Matsuura
Feb 2, 2002·The Journal of Biological Chemistry·Susan Wohler SunnarborgDavid C Lee

❮ Previous
Next ❯

Citations

Jul 9, 2013·Chemistry : a European Journal·Julien LeclaireGérard Buono
Jun 10, 2015·Translational Oncology·Victor M BlancoXiaoyang Qi
May 23, 2014·Molecular Cancer Research : MCR·Christine MehnerDerek C Radisky
Jan 15, 2011·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Sander M J van DuijnhovenHolger Grüll

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.